Search

Your search keyword '"Chevalier-Place, A."' showing total 8 results
Start Over Author "Chevalier-Place, A." Search Limiters Peer Reviewed
8 results on '"Chevalier-Place, A."'

1. A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer

Author

Blanc-Durand, Félix, Yaniz-Galende, Elisa, Llop-Guevara, Alba, Genestie, Catherine, Serra, Violeta, Herencia-Ropero, Andrea, Klein, Christophe, Berton, Dominique, Lortholary, Alain, Dohollou, Nadine, Desauw, Christophe, Fabbro, Michel, Malaurie, Emmanuelle, Bonichon-Lamaichhane, Nathalie, Dubot, Coraline, Kurtz, Jean Emmanuel, de Rauglaudre, Gaëtan, Raban, Nadia, Chevalier-Place, Annick, Ferron, Gwenael, Kaminsky, Marie-Christine, Kramer, Claire, Rouleau, Etienne, and Leary, Alexandra

Published
2023
Full Text
View/download PDF

2. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study)

Author

Robelin, Patrick, Tod, Michel, Colomban, Olivier, Lachuer, Joel, Ray-Coquard, Isabelle, Rauglaudre, Gaëtan De, Joly, Florence, Chevalier-Place, Annick, Combe, Pierre, Lortholary, Alain, Hamizi, Salima, Raban, Nadia, Ferron, Gwénaël, Meunier, Jérôme, Berton-Rigaud, Dominique, Alexandre, Jérôme, Kaminsky, Marie-Christine, Dubot, Coraline, Leary, Alexandra, Malaurie, Emmanuelle, and You, Benoit

Published
2020
Full Text
View/download PDF

3. Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor−Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.

Author

Heudel, Pierre, Frenel, Jean-Sébastien, Dalban, Cécile, Bazan, Fernando, Joly, Florence, Arnaud, Antoine, Abdeddaim, Cyril, Chevalier-Place, Annick, Augereau, Paule, Pautier, Patricia, Chakiba, Camille, You, Benoit, Lancry-Lecomte, Laurence, Garin, Gwenaelle, Marcel, Virginie, Diaz, Jean Jacques, Treilleux, Isabelle, Pérol, David, Fabbro, Michel, and Ray-Coquard, Isabelle

Published
2022
Full Text
View/download PDF

5. Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial.

Author

Ray-Coquard, Isabelle, Harter, Philipp, Lorusso, Domenica, Dalban, Cécile, Vergote, Ignace, Fujiwara, Keiichi, Gladieff, Laurence, Lück, Hans-Joachim, Floquet, Anne, Chevalier-Place, Annick, Schnelzer, Andreas, Pignata, Sandro, Selle, Frédéric, Sehouli, Jalid, Brocard, Fabien, Mangili, Giorgia, Pautier, Patricia, De Giorgi, Ugo, Provansal, Magali, and Heudel, Pierre-Etienne

Published
2020
Full Text
View/download PDF

6. Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".

Author

Blanc-Durand, Félix, Yaniz-Galende, Elisa, Llop-Guevara, Alba, Genestie, Catherine, Serra, Violeta, Herencia-Ropero, Andrea, Klein, Christophe, Berton, Dominique, Lortholary, Alain, Dohollou, Nadine, Desauw, Christophe, Fabbro, Michel, Malaurie, Emmanuelle, Bonichon-Lamaichhane, Nathalie, Dubot, Coraline, Kurtz, Jean Emmanuel, de Rauglaudre, Gaëtan, Raban, Nadia, Chevalier-Place, Annick, and Ferron, Gwenael

Subjects
*OVARIAN cancer
Published
2023
Full Text
View/download PDF

7. Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: A French multicenter phase II study

Author

Joly, F., Petit, T., Pautier, P., Guardiola, E., Mayer, F., Chevalier-Place, A., Delva, R., Sevin, E., Henry-Amar, M., and Bourgeois, H.

Subjects
*TOPOTECAN, *CANCER patients, *CANCER in women, *NEUTROPENIA, *THROMBOCYTOPENIA, *CANCER pain, *PLATINUM
Abstract

Abstract: Objectives: The aim of this phase II study was to assess the benefits of a weekly administration of topotecan and gemcitabine in patients with ovarian carcinoma having relapsed after platinum/taxane-based first-line chemotherapy. Methods: Seventy-seven patients with progression of disease ≤12 months after first-line chemotherapy were enrolled to receive topotecan (2.5 mg/m2) and gemcitabine (1000 mg/m2) on days 1, 8 and 15 (q 28 d). Primary endpoint was the response rate. Stabilization rate and symptom improvement were also assessed. Results: All patients received the combination and 66 were evaluable (≥2 cycles administered). The only major severe toxicity was neutropenia grades 3 (17%) and 4 (6%). Approximately 60% of the patients received the complete schedule of treatment, dose interruptions/delays being mainly due to moderate thrombocytopenia or neutropenia. The objective response rate was 14%, the values for patients having relapsed within 6 (n =30) and 6–12 (n =36) months being 7% and 20%, respectively. Median durations of response were 4.9 and 6.4 months and clinical benefit rates including stabilizations reached 63% and 69% in patients having relapsed within 6 or 6–12 months, respectively. Corresponding median overall survival was 7.5 and 15.6 months. Symptoms and pain were reduced in 64% and 39% of the patients concerned, respectively. Conclusion: In early relapse ovarian cancer, weekly combination of gemcitabine and topotecan has a modest objective response rate. However, a high proportion of patients experienced stable disease and symptom control leading to acceptable quality of life. [Copyright &y& Elsevier]

Published
2009
Full Text
View/download PDF

8. Carcinome à petites cellules de l'ovaire hypercalcémiant révélé par un épisode de pancréatite aiguë : à propos d'un cas

Author

Bourgain, A., Acker, O., Lambaudie, E., Boukerrou, M., Chevalier-Place, A., Meignie, P., Parent, M., Baranzelli, M.-C., Cabaret, V., Wemeau, J.-L., and Querleu, D.

Subjects
*HYPERCALCEMIA, *OVARIAN tumors, *PANCREATITIS, *CANCER cell growth
Abstract

Abstract: Small cell carcinoma of the ovary of the hypercalcemic type is a rare tumour, usually lethal and occurring almost exclusively in young patients. In the majority of described cases, signs of this lesion were revealed by the associated hypercalcemia or by virtue of the physical tumour bulk alone. We report the first case of ovarian small cell carcinoma of the hypercalcemic revealed by a severe acute pancreatitis in a 19-year-old patient. [Copyright &y& Elsevier]

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results